Claus A. Andersen

Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action

Kieran Alden, Jon Timmis, Paul R. Buckley, 2019, Front. Immunol..

Robust MS quantification method for phospho-peptides using 18O/16O labeling

Stefano Gotta, Letizia Magnoni, Roberto Raggiaschi, 2009, BMC Bioinformatics.

Brain penetration assessment in vivo: A reliable and simple method in anesthetized rats at steady state

R. Angelini, P. Perfetti, M. Bellini, 2014, Journal of Neuroscience Methods.

Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Aβ toxicity

G. Terstappen, R. Raggiaschi, A. Caricasole, 2008, Neurobiology of Disease.

Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers.

D. Diamanti, G. Pollio, B. Darpo, 2015, British journal of clinical pharmacology.

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

C. Frost, S. Tabrizi, D. Craufurd, 2015, British journal of clinical pharmacology.